Effects of Pomegranate Juice on Human Cytochrome P450 2C9 and Tolbutamide Pharmacokinetics in Rats

Masashi Nagata, Muneaki Hidaka, Hiroshi Sekiya, Yohei Kawano, Keishi Yamasaki, Manabu Okumura, and Kazuhiko Arimori

School of Pharmaceutical Sciences, Kyushu University of Health and Welfare, Miyazaki, Japan (M.N.); and Department of Pharmacy, Faculty of Medicine, University of Miyazaki Hospital, Miyazaki, Japan (M.N., M.H., H.S., Y.K., K.Y., M.O., K.A.)

Received June 29, 2006; accepted November 20, 2006

ABSTRACT:

In this study, we investigated whether pomegranate juice could inhibit CYP2C9 activity. The ability of pomegranate juice to inhibit the diclofenac 4'-hydroxylase activity of human CYP2C9 was examined using human liver microsomes. Pomegranate juice was shown to be a potent inhibitor of human CYP2C9. The addition of 25 μL (5% v/v) of pomegranate juice resulted in almost complete inhibition of human CYP2C9 activity. In addition, we investigated the effect of pomegranate juice on the pharmacokinetics of tolbutamide (substrate for CYP2C9) in rats. Relative to the control group, the area under the concentration-time curve was approximately 1.2-fold greater when pomegranate juice (3 ml) was injected p.o. 1 h before the p.o. administration of the tolbutamide (20 mg/kg). The elimination half-life of tolbutamide was not altered by pomegranate juice administration. These results suggest pomegranate juice ingestion inhibits the intestinal metabolism of tolbutamide without inhibiting the hepatic metabolism in rats. Thus, we discovered that pomegranate juice inhibited human CYP2C9 activity and furthermore increased tolbutamide bioavailability in rats.

It has been reported that some fruit juices affect the oral bioavailability of drugs. Grapefruit, star fruit, and pomelo juices increase the oral bioavailability of cytochrome P450 (P450) 3A substrates, and the mechanism of these interactions is mainly thought to be caused by the inhibition of CYP3A in the small intestine (Bailey et al., 1991, 1998; Culm-Merdek et al., 2006; Grenier et al., 2006; Hidaka et al., 2006). CYP2C9 is one of three human microsomal P450s in subfamily 2C that contributes extensively to the hepatic metabolism of therapeutic drugs (Miners and Birkett, 1998). When CYP2C9 substrates such as warfarin and phenytoin, which have low therapeutic margins, exhibit diminished metabolic rates as a result of drug-drug or drug-food interactions, these drugs could become toxic even at the normal therapeutic doses (Gilbar and Brodribb, 2001; Murphy and Wilbur, 2003; Suvanna et al., 2003). Thus, the inhibition of CYP2C9 is clinically important for the drug therapy. Furthermore, a recent report revealed that CYP2C9 is also expressed at a significant level in the human small intestine (Obach et al., 2001). Therefore, if some fruits can inhibit CYP2C9 activity in the human small intestine, then food-drug interactions may occur, similar to those observed in the case of CYP3A. However, few reports are available regarding the inhibition of CYP2C9 activity by fruit juice or fruit extracts (Greenblatt et al., 2006). Hence, it is important to evaluate the effect of fruit juice on CYP2C9 activity.

We previously reported that a component(s) of pomegranate inhibited human CYP3A activity in vitro. It almost completely inhibited midazolam 1'-hydroxylase activity and carbamazepine 10,11-epoxide activity in human liver microsomes (Hidaka et al., 2004, 2005). In addition, pomegranate altered the pharmacokinetics of carbamazepine in rats (Hidaka et al., 2005). However, it is still unknown whether pomegranate juice can inhibit CYP2C9 activity.

In the present study, we investigated whether pomegranate juice could inhibit CYP2C9-mediated drug metabolism by using human liver microsomes. We used diclofenac as a substrate for CYP2C9 because diclofenac is a recommended probe substrate for in vitro metabolic studies (Bjornsson et al., 2003). Furthermore, we investigated the effect of pomegranate juice on tolbutamide pharmacokinetics in rats because tolbutamide is also recommended as a CYP2C9 probe substrate for in vivo studies (Bjornsson et al., 2003).

Materials and Methods

Chemicals. Diclofenac and 4'-hydroxydiclofenac were obtained from Daiichi Pure Chemicals (Tokyo, Japan). Tolbutamide was purchased from Sigma-Aldrich (St. Louis, MO). Pooled human liver microsomes were obtained from Daiichi Pure Chemicals. All the chemicals and solvents were of the highest commercially available grade.

Fruit Samples. Pomegranate (California) was obtained from local commercial sources. The fruit was stored at 4°C until use. Pomegranate juice was obtained by squeezing the edible portion of the pomegranate and filtering it to remove the residue. All the samples were used within 1 h after they were squeezed and filtered.

Analytical Procedures for Human CYP2C9 Activity. Assay of diclofenac 4'-hydroxylase activity was performed according to the method of Tang et al. (2000) with minor modifications. Briefly, the incubation mixtures (final volume of 0.5 ml) consisted of the following: 0.1 M phosphate buffer, pH 7.4, 10 mM MgCl₂, 1 mM EDTA, 1 mM NADP⁺, 10 mM D-glucose 6-phosphate, 1 unit/ml D-glucose 6-phosphate dehydrogenase, and 0.1 mg/ml microsomal protein. The concentration of diclofenac was 30 μM. The reaction time was determined to be 60 min because the rate of production of the diclofenac
metabolite remained constant for up to 60 min under these conditions. The reaction mixture was applied to a fresh 10-ml tube and preincubated at 37°C for 5 min. The reaction was initiated with the addition of substrate and terminated with 2 ml of ice-cold acetonitrile. Midazolam (1 nM) was added as an internal standard. After centrifugation (3000 rpm, 10 min), the organic phase was evaporated at 40°C. The residue was dissolved in 200 μl of the high-performance liquid chromatography (HPLC) mobile phase, and 100 μl of the resultant mixture was injected into an HPLC.

**Inhibitory Effect of Pomegranate Juice on CYP2C9 Activity.** The inhibitory effect of pomegranate on P450 activity was evaluated according to our previously reported method (Hidaka et al., 2004) with minor modifications. Briefly, appropriate amounts of pomegranate juice (1, 2.5, 5, 7.5, 10, 15, 20, and 25 μl) were applied to fresh tubes. The reaction mixture described above (before the addition of substrate) was added to the tubes and mixed vigorously for 5 s. The maximum amount of fruit juice was 25 μl (5.0% v/v; the volume of the juice to the total incubation volume), and the pH of the reaction mixture was constant at 7.4 under these conditions. After preincubation at 37°C for 5 min, the substrate (diclofenac) was added. The reaction was performed as described above. The inhibitory effect of pomegranate juice on diclofenac 4'-hydroxylation was expressed as a percentage of the residual activity compared with the control in the absence of pomegranate juice. IC50 values for the inhibition of the P450 activities were determined by a nonlinear least squares regression (MULTI, Yamaoka et al., 1981) using the following equation: Residual activity (%) = 100[1 – ([I / (I + IC50)])], where I is the initial concentration of inhibitor in the microsomal incubation, γ is an exponent, and IC50 is the inhibitor concentration that inhibits enzyme activity by 50%. A similar experiment with boiled pomegranate juice (pomegranate juice that was incubated for 30 min in a boiling water bath) was conducted.

**Effect of Preincubation of Pomegranate Juice on CYP2C9 Activity.** As an index of irreversible inhibition, pomegranate juice was preincubated at 37°C for 0, 5, 10, 20, and 30 min in the reaction mixture according to the method described above.

**Animals.** Male Wistar rats (Kyuco Co., Ltd., Kumamoto, Japan) weighing 280 to 310 g and maintained at the Department of Bioresources, Division of Biotechnology (Frontier Science Research Center, University of Miyazaki) were used in this study. The Committee for the Ethics on Animal Experiments in University of Miyazaki approved the experimental protocol. The animal experiments were performed in accordance with The Guidelines for Animal Experiments of the University of Miyazaki.

**Effects of Fruit Juices on the Pharmacokinetics of Tolbutamide in Rats.** The rats had an indwelling cannula implanted in the left carotid artery under light ether anesthesia. After an overnight fast, 3 ml of pomegranate juice or 5% glucose in phosphoric acid (pH 3) was p.o. administered by gastric intubation. Because the pH of the fruit juices was approximately 3, we administered 5% glucose in phosphoric acid to the control rats. Tolbutamide was dissolved in 0.02 M sodium hydroxide (3 mg/ml) and administered p.o. at a dose of 20 mg/kg, 1 h after the injection of fruit juice or 5% glucose in phosphoric acid. Blood samples were drawn periodically through the cannula introduced into the carotid artery at 0, 15, and 30 min and 1, 2, 4, 6, 8, and 12 h after tolbutamide administration. Blood samples were immediately centrifuged at 13,000 g for 5 min, and the serum was separated. The collected serum samples were stored at −20°C until HPLC analysis.

**Assay of Tolbutamide or Glucose Concentration in Serum.** For the determination of tolbutamide in serum, 50 μl of serum and 100 μl of acetonitrile were mixed vigorously for 10 s and then centrifuged at 13,000 g for 5 min. Fifty microliters of supernatant and 20 μl of 0.02 M sodium hydroxide were mixed, and 20 μl of the mixture was injected onto the HPLC column. The serum concentration of glucose was determined by the glucose oxidase method using a Glucose CII-test Wako (Wako Pure Chemical Industries, Osaka, Japan).

**HPLC Conditions.** The HPLC system consisted of an LC-10ADvp pump (Shimadzu, Kyoto, Japan), a Shimadzu L-4200 UV absorbance detector, a Shimadzu SIL-10A vp auto injector, and a Shimadzu SCL-10Avp system controller. The system was equipped with a Watanuki CD-C18 column (3 μm, 4.6 × 250 mm; Intact, Kyoto, Japan) preceded by a precolumn (5 μm, 2 × 5 mm). The mobile phase for diclofenac metabolite consisted of acetonitrile and 0.1% of phosphoric acid (50:50, v/v). The mobile phase for tolbutamide consisted of acetonitrile (20:80) in 0.1% of pH 7.4 phosphate buffer (solvent A) and acetonitrile (solvent B). The initial mobile phase was delivered at a flow rate of 0.7 ml/min at 40°C. Quantification was performed by determining the UV peak areas monitored (at 274 nm for the diclofenac metabolite and 230 nm for tolbutamide).

**Pharmacokinetic Analysis.** The peak plasma concentration (Cmax) and the time required to reach Cmax (Tmax) of tolbutamide were obtained from the actual data recorded after p.o. administration. The elimination half-life (t1/2) was calculated by dividing the natural logarithm of 2 by kel, which is the apparent elimination rate constant that is obtained from the elimination phase slope. The area under the concentration-time curve (AUC) and mean residence time were estimated by moment analysis (Yamaoka et al., 1978).

**Statistical Analysis.** Pharmacokinetic parameters were expressed as the geometric mean and 90% confidence intervals. All the other results were expressed as the arithmetic mean ± S.D. Differences in the sample means between two groups were evaluated by the F test for equality of variances followed by a Student’s t test or Welch’s t test. Differences were considered significant at p < 0.05.

**Results**

**Inhibitory Effect of Pomegranate Juice on CYP2C9 Activity in Vitro.** To examine the effects of pomegranate juice on CYP2C9 activity, we investigated diclofenac 4'-hydroxylase activity with or without pomegranate juice by using human liver microsomes. As shown in Fig. 1, the inhibitory effect of pomegranate juice on CYP2C9 activity depended on the amount of pomegranate juice added to the reaction mixture. The addition of 25 μl (5% v/v) of pomegranate juice resulted in almost complete inhibition of human CYP2C9 activity. The mean IC50 value determined for pomegranate juice was 4.84 μl (0.97% v/v). The inhibition potency of pomegranate juice for CYP2C9 was found to be similar to that for CYP3A (Hidaka et al., 2005). The mean IC50 value determined for boiled pomegranate juice was 5.03 μl (1.01% v/v). There was no difference in the inhibition potency for CYP2C9 between pomegranate juice and boiled pomegranate juice. These results suggest that the inhibitory effect of pomegranate juice would not be caused by a proteolytic activity contained in the juice.

To evaluate whether pomegranate juice inhibits CYP2C9 enzyme in a mechanism-based manner, we next investigated the effect of the length of the preincubation period on the inhibition of diclofenac 4'-hydroxylase activity by pomegranate juice. The inhibition potency of pomegranate juice was altered by elongation of the preincubation period (Fig. 2). The mean residual CYP2C9 activities observed with pomegranate juice (1 μl) at the preincubation times of 0.5, 10, 20, and 30 min were 95.0, 89.8, 84.6, 82.4, and 79.7%, respectively. The activities observed with pomegranate juice (5 μl) were 65.9, 55.1,
significantly increased the AUC of tolbutamide by 22%. The tolbutamide concentrations between 5% glucose in phosphoric acid-pharmacokinetics. There was no significant difference in serum shown in Fig. 3 and Table 1. In a preliminary study, we investigated of pomegranate juice with tolbutamide might alter the pharmacoki- butamide in Rats.

Because pomegranate juice strongly inhibited granate juice contains a mechanism-based inhibitor(s).

49.8, 42.8, and 38.3%, respectively. These results suggest that pomegranate juice contains a mechanism-based inhibitor(s).

Effects of Pomegranate Juice on the Pharmacokinetics of Tol- butamide in Rats. Because pomegranate juice strongly inhibited CYP2C9 activity in vitro, we wondered whether the coadministration of pomegranate juice with tolbutamide might alter the pharmacokinetics of tolbutamide. Therefore, we investigated the effect of pomegranate juice on tolbutamide pharmacokinetics in rats. Results are shown in Fig. 3 and Table 1. In a preliminary study, we investigated whether 5% glucose in phosphoric acid by itself could alter tolbutamide pharmacokinetics. There was no significant difference in serum tolbutamide concentrations between 5% glucose in phosphoric acid-treated rats and water-treated rats (data not shown). Pomegranate juice significantly increased the AUC of tolbutamide by 22%. The 1/2, Tmax, and mean residence time of tolbutamide in pomegranate-treated rats were not significantly different from those of their controls. These results suggest that pomegranate juice increases tolbutamide bioavailability in rats.

Effects of Pomegranate Juice on Tolbutamide Efficacy in Rats. A preliminary study, 3 ml of pomegranate juice or 5% glucose in phosphoric acid (pH 3) was p.o. administered by gastric intubation to rats. There was no significant difference in serum glucose level-time profiles between pomegranate-treated rats and their controls (data not shown).

Time-dependent changes in the serum glucose concentrations after p.o. administration of tolbutamide in rats are shown in Fig. 4. The reduction of serum glucose levels in pomegranate-treated rats tended to be low compared with that of the control rats, but there was no statistical significance between the two groups.

Discussion

Recently, there have been many reports regarding food-drug inter- actions by the inhibition of drug metabolism mediated by the CYP3A subfamily. However, few reports are available on the inhibition of CYP2C9 activity by fruit juices or the extracts. In this study, we discovered that pomegranate juice inhibited human CYP2C9 activity in vitro. This result suggests that pomegranate juice may affect the pharmacokinetics of substrates for CYP2C9 in humans.

Pomegranate is a rich source of several chemicals such as pectin, tannins, flavonoids, and anthocyanins (Gil et al., 2000; Aviram et al., 2002; Noda et al., 2002). If pomegranate also includes an unidentified protease, the effect observed in vitro with human microsomes may be caused by the proteolytic activity of the juice. Therefore, we used boiled pomegranate juice to determine whether the inhibition of CYP2C9 activity in vitro was caused by the proteolytic activity within the juice or by specific inhibition of the CYP2C9 by a component of the juice. In this study, there was no difference in the mean IC50 value between pomegranate juice (4.84 μl) and boiled pomegranate juice (5.03 μl). This result suggests that the inhibitory effect of pomegranate is not caused by proteolytic activity of the juice because the protein components of the juice would have been inactivated by boiling.

Tolbutamide, an oral hypoglycemic drug, is mainly metabolized by CYP2C9 (Miners and Birkett, 1998). It has been reported that the coadministration of sulfaphenazole (a CYP2C9 inhibitor) (Venkataraman et al., 2001) increased the serum concentration of tolbutamide and induced severe hypoglycemia (Christensen et al., 1963). If pomegranate juice could inhibit the CYP2C9 that is expressed in the small intestine and/or the liver, it could increase the serum concen-
tration of tolbutamide and potentially induce hypoglycemia. Therefore, we further investigated whether pomegranate juice could affect the pharmacokinetics of tolbutamide in rats. The results showed that the coadministration of pomegranate juice significantly increased the AUC of tolbutamide by 22%. Furthermore, the half-life, which reflects the elimination of tolbutamide, was not altered by pomegranate juice. These results suggest that the increased serum concentrations of tolbutamide in pomegranate juice-treated rats would be caused by an increase in tolbutamide bioavailability.

P-glycoprotein plays an important role in the pharmacokinetics of substrate drugs, i.e., in their absorption, distribution, and elimination, with resulting low oral bioavailability of these drugs. It is well known that there is an overlap between the inhibitors for CYP3A and P-glycoprotein (Kim et al., 1999). Because pomegranate juice is an inhibitor of CYP3A (Hidaka et al., 2005), the juice may be also an inhibitor of P-glycoprotein in the intestine and enhance the absorption of drugs. However, Nishimura et al. (2004) reported that basolateral-to-apical transport of tolbutamide across the Caco-2 cell monolayers was not operated by the carrier-mediated transport system including P-gp efflux. Therefore, the inhibition of P-glycoprotein by pomegranate juice likely would not be associated with the increased bioavailability of tolbutamide.

In this study, serum glucose levels after tolbutamide administration in pomegranate-treated rats were lower than the values in their controls, but these differences were not statistically significant. This result suggests that the 22% increase in AUC of tolbutamide by pomegranate juice ingestion would not affect the efficacy of tolbutamide very much. Therefore, even if pomegranate juice can increase the tolbutamide concentration in humans, this interaction may not be of clinical significance.

On the other hand, in vitro data on metabolic inhibition do not necessarily translate into drug interactions in vivo. Although grape juice, tea, cranberry juice, and a number of natural compounds present in Ginkgo biloba impaired CYP2C9 activity in vitro, these beverages and compounds did not alter CYP2C9-mediated clearance of flurbiprofen in humans (von Moltke et al., 2004; Greenblatt et al., 2006a,b). Furthermore, Eagling et al. (1998) reported that caution must be exercised when extrapolating the effects of inhibitors from rats to humans. For example, sulphenazolo selectively inhibited tolbutamide hydroxylation in human liver microsomes but failed to inhibit this reaction in rat liver microsomes (Eagling et al., 1998). In addition, the effects of fruit juice on the pharmacokinetics of drugs in rats are not necessarily consistent with those in humans (Spahn-Langguth and Langguth, 2001; Schwarz et al., 2005). Therefore, further investigations in humans are necessary to elaborate our findings.

In conclusion, we showed that pomegranate juice inhibited human CYP2C9 activity. Furthermore, pomegranate juice increased tolbutamide bioavailability in rats.

Acknowledgments. We thank Dr. Yutaka Matsuoka (Tokyo University of Science, Japan) for useful advice on the statistical analysis.

References

Address correspondence to: Masashi Nagata, School of Pharmaceutical Sciences, Kyushu University of Health and Welfare, 1714-1 Yushima, Nobeoka City, Miyazaki, 882-8508, Japan. E-mail: m-nagata@phoenix.ac.jp